scholarly journals BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis

2021 ◽  
Author(s):  
Tommy Nyberg ◽  
Marc Tischkowitz ◽  
Antonis C. Antoniou
Keyword(s):  
Prostate Cancer ◽  
Risk Estimation ◽  
Meta Analysis ◽  
Prostate Cancer Risk ◽  
European Ancestry ◽  
Cochrane Library ◽  
Brca1 And Brca2 ◽  
Relative Risks ◽  
Pathogenic Variants ◽  
Wide Range

Abstract Background BRCA1 and BRCA2 pathogenic variants (PVs) are associated with prostate cancer (PCa) risk, but a wide range of relative risks (RRs) has been reported. Methods We systematically searched PubMed, Embase, MEDLINE and Cochrane Library in June 2021 for studies that estimated PCa RRs for male BRCA1/2 carriers, with no time or language restrictions. The literature search identified 27 studies (BRCA1: n = 20, BRCA2: n = 21). Results The heterogeneity between the published estimates was high (BRCA1: I2 = 30%, BRCA2: I2 = 83%); this could partly be explained by selection for age, family history or aggressive disease, and study-level differences in ethnicity composition, use of historical controls, and location of PVs within BRCA2. The pooled RRs were 2.08 (95% CI 1.38–3.12) for Ashkenazi Jewish BRCA2 carriers, 4.35 (95% CI 3.50–5.41) for non-Ashkenazi European ancestry BRCA2 carriers, and 1.18 (95% CI 0.95–1.47) for BRCA1 carriers. At ages <65 years, the RRs were 7.14 (95% CI 5.33–9.56) for non-Ashkenazi European ancestry BRCA2 and 1.78 (95% CI 1.09–2.91) for BRCA1 carriers. Conclusions These PCa risk estimates will assist in guiding clinical management. The study-level subgroup analyses indicate that risks may be modified by age and ethnicity, and for BRCA2 carriers by PV location within the gene, which may guide future risk-estimation studies.

scholarly journals Association between SLCO1B3 gene polymorphism and prostate cancer risk: A meta-analytic study

2018 ◽  
Vol 13 (1) ◽  
pp. 98
Author(s):  
Qunshan Shen ◽  
Yu Liang ◽  
Haibo Li ◽  
Mei Chen ◽  
Jun Zhang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Gene Polymorphism ◽  
Web Of Science ◽  
Prostate Cancer Patient ◽  
Meta Analysis ◽  
Prostate Cancer Risk ◽  
Risk Of Bias ◽  
Cochrane Library ◽  
Statistical Relationship

<p class="Abstract">The aim of this meta-analysis was to assess the association between SLCO1B3 gene polymorphism and prostate cancer risk. PubMed, Embase, Cochrane Library, and Web of Science from inception to September 2017 were searched. Three authors independently selected studies, extracted data and assessed risk of bias. 5 articles published from 2008 to 2013 with 840 patients were included in this meta-analysis and were from Japan, USA and China. The prostate cancer risk of SLCO1B3 (rs4149117, GG) was markedly higher than that of SLCO1B3 (rs4149117, TT/TG, RR= 0.44, 95%CI: 0.39-0.49, p&lt;0.00001), rs4149117 (TT, RR= 0.37, 95%CI: 0.32-0.42, p&lt;0.00001) and rs4149117 (TG, RR= 0.07, 95%CI: 0.05-0.10, p&lt;0.00001). 2 or 5 years risk  free symptoms (RFS) of prostate cancer patient with SLCO1B3 (rs4149117, GG) was markedly higher than that of SLCO1B3 (rs4149117, TT/TG) (RR= -0.17, 95% CI: -0.27--0.07, p= 0.001 and RR= -0.08, 95% CI: -0.16-0.00, p= 0.004). However, no evidence showed there existed significant statistical relationship between SLCO1B3 (rs4149117) and 10 years RFS of prostate cancer (RR= -0.07, 95% CI: -0.19-0.06, p= 0.29). These data suggest that SLCO1B3 (rs4149117, GG) enhanced the RFS of prostate cancer.</p>

scholarly journals The CYP19A1 (TTTA)n Repeat Polymorphism May Affect the Prostate Cancer Risk: Evidence from a Meta-Analysis

2021 ◽  
Vol 15 (3) ◽  
pp. 155798832110170
Author(s):  
Lei Guo ◽  
Yanan Liu ◽  
Lijun Liu ◽  
Shixiu Shao ◽  
Yanwei Cao ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Meta Analysis ◽  
Prostate Cancer Risk ◽  
Population Based ◽  
Cochrane Library ◽  
Repeat Polymorphism ◽  
Repeat Allele ◽  
Major Allele ◽  
The Impact ◽  
Allelic Model

Abnormal aromatase (CYP19A1) expression may participate in prostate cancer (PCa) carcinogenesis. However, the results of studies on the CYP19A1 gene polymorphisms and PCa are conflicting. This meta-analysis aimed to systematically evaluate the associations between the CYP19A1 Arg264Cys polymorphism and the (TTTA)n repeat polymorphism and PCa. Electronic databases (PubMed, EmBase, ScienceDirect, and Cochrane Library) were comprehensively searched to identify eligible studies. The strength of the association between the Arg264Cys polymorphism and PCa was assessed by pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) in allelic, dominant, recessive, homozygous, and heterozygous genetic models. To analyze the impact of the (TTTA)n repeat polymorphism, we sequentially took the N-repeat allele (where N equals 7,8,10,11,12, and 13) as the minor allele and the sum of all the other alleles as the major allele. The ORs and 95% CIs were calculated in the allelic model; this analysis was performed individually for each repeat number. Pooled estimates of nine studies addressing the Arg264Cys polymorphism indicated that this polymorphism was not associated with PCa risk in the overall population or in the Caucasian or Asian subgroups. The 8-repeat allele in the (TTTA)n repeat polymorphism increased PCa risk in the overall population (OR = 1.34, 95% CI = 1.14–1.58, p = .001) and in the subgroup with population-based (PB) controls (OR = 1.41, 95% CI = 1.13–1.74, p = .002) as well as in the subgroup using capillary electrophoresis to identify this polymorphism (OR = 1.34, 95% CI = 1.09–1.65, p = .006).The meta-analysis indicated that the CYP19A1 (TTTA)n repeat polymorphism, but not the Arg264Cys polymorphism, may affect PCa risk.

scholarly journals BARIUM LEVELS IN THE PROSTATE OF THE NORMAL HUMAN: A REVIEW

2021 ◽  
Author(s):  
Vladimir Zaichick
Keyword(s):  
Prostate Cancer ◽  
Peer Review ◽  
Prostate Cancer Risk ◽  
Serum Levels ◽  
Cochrane Library ◽  
Interleukin 22 ◽  
Impaired Liver ◽  
Wide Range ◽  
Liver And Kidney ◽  
Review Reports

Knowledge of the etiology and pathogenesis of most prostate malfunctions and pathologies is very limited. Despite advances in medicine, the differential diagnosis of benign hypertrophic and carcinogenic prostate has steadily increased in complexity and controversy. It has been suggested that the prostate barium level (Ba) may help solve these problems related to prostate disorders, especially as an indicator of prostate cancer risk, as an elevated Ba level in the prostate may be a sign of prostate cancer in the future. These suggestions promoted more detailed studies of the Ba level in the prostate of healthy men. In present review we analyze data published concerning Ba prostatic levels in healthy persons.  In all 2194 items in the literature of the years dating back to 1921 were identified in the following databases: PubMed, Scopus, Web of Science, the Cochrane Library, ELSEVIER-EMBASE and Google.  This data was subject to an analysis employing both the “range” and “median” of means.  In this way the disparate nature of published Ba content of normal prostates was evaluated. Of the articles examined, 20 were selected for objective analysis of data from 1049 healthy subjects. The contents of prostatic Ba (on a wet mass basis) spanned the interval from 0.021 mg/kg to 222 mg/kg with 0.26 mg/kg as median for their means. The data included a wide range of values ​​and the samples were small, hence it is advisable that further studies with strong quality control of results be performed.                     Peer Review History: Received 10 January 2021; Revised 2 February; Accepted 4 March, Available online 15 March 2021 UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency.  Received file:                Reviewer's Comments: Average Peer review marks at initial stage: 6.5/10 Average Peer review marks at publication stage: 8.5/10 Reviewer(s) detail: Dr. U. S. Mahadeva Rao, Universiti Sultan Zainal Abidin, Terengganu Malaysia, [email protected] Prof. Dr. Hassan A.H. Al-Shamahy, Sana'a University, Yemen, [email protected] Similar Articles: LEVEL OF LEAD IN THE BLOOD AMONG FUEL STATION EMPLOYEES AND ITS RELATIONSHIP TO IMPAIRED LIVER AND KIDNEY FUNCTIONS IN DAMASCUS; SYRIA: OCCUPATIONAL EXPOSURE TO LEAD  INTERLEUKIN-22 SERUM LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SANA'A CITY, YEMEN  PLASMA FERRITIN AND HEPCIDIN LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

The association of BRCA1 and BRCA2 mutations on prostate cancer risk, frequency, and mortality: Systematic review and meta-analysis.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 5060-5060
Author(s):  
Mok Oh ◽  
Rana Aljadeed ◽  
Nasser Mubarak Al Khushaym ◽  
Abdulhamid Althagafi ◽  
Saad Fallatah ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Cancer Risk ◽  
Meta Analysis ◽  
Prostate Cancer Risk ◽  
Brca1 And Brca2 ◽  
Brca2 Mutations ◽  
Brca1 And Brca2 Mutations

scholarly journals Dietary Tomato Consumption and the Risk of Prostate Cancer: A Meta-Analysis

2021 ◽  
Vol 8 ◽  
Author(s):  
Jie Luo ◽  
Dandan Ke ◽  
Qingwei He
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Cohort Studies ◽  
Large Scale ◽  
Meta Analysis ◽  
Prostate Cancer Risk ◽  
Epidemiological Studies ◽  
Relative Risks ◽  
Tomato Products ◽  
Meta Analyses

Objective: Several epidemiological studies have linked tomato products consumption with prostate cancer risk; however, the findings yielded inconsistent results. The aim of the present meta-analysis is to summary the evidence on this association based on eligible cohort studies.Materials and Methods: A comprehensive literature search of articles was performed in March 2021 using PubMed, ISI Web of Science, and Scopus databases. A random-effects model was used to calculate the combined relative risks (RRs) and their corresponding 95% confidence intervals (CIs). Heterogeneity across studies was assessed using Cochran's Q statistic and the I2 score.Results: A total of 10 prospective studies were finally included in our meta-analysis. There was no evidence of a significant association between tomato products consumption and prostate cancer risk (RR 0.91, 95% CI 0.79–1.03, P = 0.138). Subgroup meta-analyses were performed by tomato types, geographical region, publication year, study quality and number of cases. No significant associations were observed in any subgroups (all P &gt; 0.05). No significant publication bias was observed using Begg's test (P = 0.602) or Egger's test (P = 0.957).Conclusion: The results of this meta-analysis indicated that tomato consumption was not related with the risk of prostate cancer. Further prospective large-scale cohort studies are still warranted to verify our findings.

scholarly journals Inflammatory Bowel Disease and the Risk of Prostate Cancer: A Meta-analysis of Cohort Studies

2019 ◽  
Author(s):  
Wen-Qing Lian ◽  
Hong-Xing Huang ◽  
Fa-Jiang Li ◽  
Liang-Hua Chen
Keyword(s):  
Prostate Cancer ◽  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Cancer Risk ◽  
Cohort Studies ◽  
Bowel Disease ◽  
Meta Analysis ◽  
Prostate Cancer Risk ◽  
Cochrane Library ◽  
Inflammatory Bowel

Abstract Purpose This meta-analysis aims to assess the prostate cancer risk in patients with inflammatory bowel disease (IBD). Methods A systematic search was conducted on PubMed, EMBASE, and the Cochrane Library databases for eligible studies published before April 2019. Pooled relative ratios (RRs) and 95% confidence intervals (CIs) were estimated to evaluate the relationship between history of IBD and prostate cancer risk. Results Fourteen publications involving thirteen cohort studies were eligible. The meta-analysis showed that IBD markedly elevated risk of prostate cancer (RR 1.36, 95% CI 1.11-1.67). Subgroup analysis by subtype of IBD showed that ulcerative colitis was associated with a statistically significant increase in risk of prostate cancer (RR 1.30, 95%CI 1.09-1.55), while Crohn's disease was not (RR 1.09, 95%CI 0.90-1.34). Conclusion The present meta-analysis indicates that IBD increases the risk of prostate cancer, particularly in ulcerative colitis men. More prospective cohort studies are required to confirm our findings.

scholarly journals Comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer: a protocol for systematic review and meta-analysis

2021 ◽  
Vol 52 (1) ◽  
Author(s):  
Garba Haruna Yunusa ◽  
Aminu Umar Kaoje ◽  
Akintunde Taiwo Orunmuyi ◽  
Stuart S. More ◽  
Zabah Muhammad Jawa ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Service Providers ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Suitable Alternative ◽  
Psma Pet ◽  
Pet Ct ◽  
Statistical Heterogeneity ◽  
Wide Range

Abstract Background A wide range of nuclear imaging probes have been developed to address different metabolic processes and cell receptors in prostate cancer patients using positron emission techniques to aid diagnosis, staging, and monitoring for recurrence after treatment. While 68Ga PSMA is a generator-derived PET radiopharmaceutical, SPECT/CT imaging using technetium-99m-labeled PSMA is now available as a suitable alternative. The aim of this study is to compare the pooled sensitivity, specificity, and accuracy of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer. Main body of the abstract A search strategy was developed using text words, MeSH, and entry terms. The following databases will be searched: PubMed, African Journals Online (AJOL), Embase, Google scholar, ResearchGate, Cochrane Library, Scopus, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Web of Science. Eligibility criteria include (a) all studies that are published or retrievable in English language, (b) observational studies, and (c) histopathology analysis or clinical and imaging follow-up or comparison with reference standards. Exclusion criteria will be interventional studies, editorials, reviews, and commentaries. Quality of the studies will be assessed using QUADAS2 Quality scores and risk of bias for individual studies will be reported. Full text of the studies will be reviewed and snowballed for any relevant literature. Assessment of methodological, clinical, and statistical heterogeneity for all the included studies will be made. Publication bias will be assessed using funnel plots. Statistical analysis and forest plots will be performed using the Open Meta-analyst software. The systematic review and meta-analysis will be reported according to PRISMA 2015 Statement. Short conclusion This review will provide data on diagnostic accuracy of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer. Results from this study will help nuclear medicine service providers to make better decisions on the appropriate use of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT especially with regard to the use of 99mTc-PSMA SPECT/CT which is relatively affordable and more readily available in developing countries when compared to 68-Ga PSMA PECT/CT.

Coffee Consumption and Prostate Cancer Risk: A Meta-Analysis of Cohort Studies

2015 ◽  
Vol 67 (3) ◽  
pp. 392-400 ◽  
Author(s):  
Huan Liu ◽  
Guang-Hui Hu ◽  
Xing-Chun Wang ◽  
Tian-Bao Huang ◽  
Liang Xu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Cohort Studies ◽  
Meta Analysis ◽  
Prostate Cancer Risk ◽  
Coffee Consumption

scholarly journals Prostate cancer risk variants of the HOXB genetic locus

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
William D. Dupont ◽  
Joan P. Breyer ◽  
Spenser H. Johnson ◽  
W. Dale Plummer ◽  
Jeffrey R. Smith
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Cancer Genetics ◽  
Genetic Locus ◽  
Familial Cancer ◽  
Prostate Cancer Risk ◽  
European Ancestry ◽  
Ovarian Cancer Screening ◽  
Hereditary Prostate Cancer ◽  
Aggressive Disease

AbstractThe G84E germline mutation of HOXB13 predisposes to prostate cancer and is clinically tested for familial cancer care. We investigated the HOXB locus to define a potentially broader contribution to prostate cancer heritability. We sought HOXB locus germline variants altering prostate cancer risk in three European-ancestry case–control study populations (combined 7812 cases and 5047 controls): the International Consortium for Prostate Cancer Genetics Study; the Nashville Familial Prostate Cancer Study; and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Multiple rare genetic variants had concordant and strong risk effects in these study populations and exceeded genome-wide significance. Independent risk signals were best detected by sentinel variants rs559612720 within SKAP1 (OR = 8.1, P = 2E−9) and rs138213197 (G84E) within HOXB13 (OR = 5.6, P = 2E−11), separated by 567 kb. Half of carriers inherited both risk alleles, while others inherited either alone. Under mutual adjustment, the variants separately carried 3.6- and 3.1-fold risk, respectively, while joint inheritance carried 11.3-fold risk. These risks were further accentuated among men meeting criteria for hereditary prostate cancer, and further still for those with early-onset or aggressive disease. Among hereditary prostate cancer cases diagnosed under age 60 and with aggressive disease, joint inheritance carried a risk of OR = 27.7 relative to controls, P = 2E−8. The HOXB sentinel variant pair more fully captured genetic risk for prostate cancer within the study populations than either variant alone.

Effect of Statins on the Risk of Different Stages of Prostate Cancer: A Meta-Analysis

2021 ◽  
pp. 1-9
Author(s):  
Yun Li ◽  
Xuan Cheng ◽  
Jia-lian Zhu ◽  
Wen-wen Luo ◽  
Huai-rong Xiang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lower Risk ◽  
Advanced Prostate Cancer ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Low Grade ◽  
High Grade ◽  
The Cochrane Library ◽  
The Relationship ◽  
Comprehensive Literature Search

<b><i>Introduction:</i></b> The aim of this article was to investigate the relationship between statins and the risk of different stages or grades of prostate cancer. <b><i>Methods:</i></b> A comprehensive literature search was performed for articles published until December 18, 2020, on the PubMed, Embase, and the Cochrane Library databases. The pooled relative risk (RR) and 95% confidence interval (CI) were then analyzed using the STATA.16.0 software. <b><i>Results:</i></b> A total of 588,055 patients from 14 studies were included in the analysis. We found that the use of statins expressed a significant correlation with a lower risk of advanced prostate cancer (RR = 0.81, 95% CI: 0.73–0.91; RR = 0.86, 95% CI: 0.75–0.99, respectively). However, no evidence suggested that the use of statins was beneficial for the prevention of localized prostate cancer incidence. Similarly, the pooled results also revealed no association between the use of statins and the risk of high-grade and low-grade prostate cancer. <b><i>Conclusion:</i></b> It has been found that the use of statins is associated with a lower risk of advanced prostate cancer but was not related to the risk of localized, low-grade, or high-grade prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document